Диссертация (1140133), страница 17

Просмтор этого файла доступен только зарегистрированным пользователям. Но у нас супер быстрая регистрация: достаточно только электронной почты!

Текст из файла (страница 17)

417-428.184. Scheinfeld, N.S. Melasma / N.S. Scheinfeld // Skinmed. – 2007. – 6. - P. 357.185. Scott, M.C. Regulation of the human melanocortin 1 receptor expression inepidermal melanocytes by paracrine and endocrine factors and by ultravioletradiation / M.C. Scott, I. Suzuki, Z.A. Abdel-Malek // Pigment Cell Res. –2002. – 15. - P. 433–439.186. Sharquie, K.E. Topical 10% zinc sulfate solution for treatment of melisma /K.E. Sharquie, S.A. Al-Mashhadani, H.A. Salman // Dermatol Surg.

– 2008. –34. – P. 1346-1349.187. Sheth, V.M. Melasma: a comprehensive update: part II / V.M. Sheth, A.G.Pandya // J Am Acad Dermatol. – 2011. – 65 (4). – P. 699–714.188. Sialy, R. Melasma in men: a hormonal profile / R. Sialy [et al.] // J Dermatol.– 2000. – 27. – P. 64-5.189. Situm, M. Melasma-updated treatments / M. Situm [et al.] // Coll Antropol. –2011. - 35 (2).

– P. 315-318.190. Stemmer-Rachamimov, A.O. NHE-RF, a merlin-interacting protein, isprimarily expressed in luminal epithelia, proliferative endometrium, andestrogen receptorpositive breast carcinomas / A.O. [et al.] // Am J Pathol. –2001. – 158. – P. 57–62.191. Suzuki, I. Participation of the melanocortin-1 receptor in the UV control ofpigmentation / I. Suzuki [et al.] // J. Investig. Dermatol. Symp.

Proc. – 1999. –4. – P. 29–34.106192. Tamega, A. Clinical patterns and epidemiological characteristics of facialmelasma in Brazilian women / A. Tamega [et al.] // J Eur Acad DermatolVenereol. – 2013. – 27. – P. 151–156.193. Tamega, A. Gene and protein expression of oestrogen-β and progesteronereceptors in facial melasma and adjacent healthy skin in women / A. Tamega[et al.] // Int.

J. Cosmet. Sci. – 2015. – 37. - P. 222–228.194. Thornton, M.J. The biological actions of estrogens on skin / M.J. Thornton //Exp. Dermatol. – 2002. – 11. – P. 487–502.195. Torok, H.M. A comprehensive review of the longterm and short-termtreatment of melasma with a triple combination cream / H.M. Torok // Am JClin Dermatol. – 2006. – 7 (4). – P.

223–30.196. Torok, H.M. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide0.01%: a safe and efficacious 12 month treatment for melasma / H.M. Torok[et al.] // Cutis. – 2005. – 75. – P. 57-62.197. Tse, T.W. Tranexamic acid: an important adjuvant in the treatment ofmelisma / T.W. Tse, E. Hui // J Cosmet Dermatol. – 2013. – 12. – P. 57-66.198. Tzouveka, E. Epidemiology and Risk Factors of Melasma / E. Tzouveka //Pigmentary Disorders. – 2014. - S1:002.199. Vermeulen, A.

Hormonal effects of a 5 alpha-reductase inhibitor (finasteride)on hormonal levels in normal men and in patients with benign prostatichyperplasia / A. Vermeulen [et al.] // Eur. Urol. – 1991. – 20. – P. 82–86.200. Victor, F.C. Melasma: a review / F.C. Victor, J. Gelber, B. Rao // J CutanMed Surg. – 2004. – 8 (2).

– P. 97-102.201. Wiedemann, C. (2009). Inhibitory effects of progestogens on the estrogenstimulation of melanocytes in vitro / C. Wiendemann [et al.] // Contraception.– 2009. – 80. – P. 292–298.202. Wu, I.B. Melasma / I.B. Wu [et al.] // G Ital Dermatol Venereol. – 2012. –147. – P. 413–418.203. Wu, S.

Treatment of melasma with oral administration of tranexamic acid / S.Wu [et al.] // Aesthetic Plast Surg. – 2012. – 36. – P. 964–70.107204. Yazdanfar, A. Association of melasma with thyroid autoimmunity: a casecontrol study / A. Yazdanfar, B. Hashemi // Iran J Dermatol. – 2010.

- 13. – P.51-53.205. Zaleski, L. Treatment of melasma and the use of intense pulsed light: a review/ L. Zaleski, S. Fabi, M.P. Goldman // J Drugs Dermatol. – 2012. – 11. – P.1316-1320.206. Zhu, H.J. The clinical study of acidum tranexamicum on melisma / H.J. Zhu,X.H. Yang // Pharm Prog. – 2001. – 3. – P. 178-181.108.

Характеристики

Список файлов диссертации